Current cancer drug targets最新文献

{"title":"Machine Vision Approaches for Cervical Cancer Screening Using Pap-Smear Images: A Systematic Review.","authors":"R John Martin, Mithlesh Arya, Jayabrabu Ramakrishnan, Santhosh Joseph Menachery, Ruchi Mittal, Sujatha S, Santhi Muttipoll Dharmarajlu, Nadim Rana","doi":"10.2174/0115680096398033251128082310","DOIUrl":"https://doi.org/10.2174/0115680096398033251128082310","url":null,"abstract":"<p><p><P> Introduction: Cervical cancer continues to be a predominant cause of cancer-related mortality in women, especially in developing nations where its incidence is significantly raised. The Pap smear test is extensively utilized for early detection, and machine learning algorithms have evolved as effective strategies to improve diagnostic accuracy and efficacy. </P> <P> Methods: This systematic review, guided by PRISMA, analyzes recent machine vision-based frameworks designed for cervical cancer screening using Pap smear images. This research was classified into three primary methodological domains: segmentation, feature extraction, and classification. Besides, commonly utilized datasets were examined to evaluate their validity and relevance for cervical cancer screening applications. </P> <P> Results: This review synthesizes the methods chosen and essential elements necessary for the design of effective machine learning-based screening systems. Deep learning methods demonstrated improved accuracy when utilized with extensive annotated datasets. The absence of high-quality multi-cell datasets and inconsistencies in evaluation practices hinder comparable options among studies. </P> <P> Discussion: Results show that, despite significant progress, no single framework consistently outperform others in all contexts. Deep learning-based and hybrid models demonstrate significant potential; but, variability in datasets and evaluation methods limits their generalization and clinical implementation. Improving reproducibility and reliability necessitates addressing dataset quality, annotation standards, and benchmarking practices. </P> <P> Conclusion: This review considers the strengths and limitations of existing approaches and offers practical insights for the advancement of cervical cancer screening research. Future research must focus on the creation of standardized datasets and evaluation frameworks to improve clinical applicability and guarantee the robustness and scalability of diagnostic systems.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147455856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural Product-Based Therapeutic Strategies Targeting Signaling Pathways in Prostate Cancer: A Comprehensive Review.","authors":"Riya Chaudhary, Arbab Husain, Afreen Khanam, Pratibha Pandey, Fahad Khan","doi":"10.2174/0115680096404959251120100154","DOIUrl":"https://doi.org/10.2174/0115680096404959251120100154","url":null,"abstract":"<p><p>Prostate Cancer (PCa) remains one of the leading causes of cancer-related death among men globally. While numerous traditional treatments like chemotherapy, radiation ther-apy, and surgical procedures exist, they often exhibit challenges due to drug resistance mech-anisms, off-target effects, and severe toxicity to normal tissues. Hence, finding other low-tox-icity therapeutic methods is of utmost importance. This review summarizes the ability of nat-ural product-derived therapies to target critical signaling pathways involved in PCa progres-sion, including the Androgen Receptor (AR), PI3K/AKT/mTOR, JAK/STAT, MAPK, and NF-κB pathways. Curcumin, resveratrol, genistein, and sulforaphane are natural compounds that exhibit anticancer effects by regulating these molecular pathways, thereby inhibiting tu-mor growth, inducing apoptosis, and preventing metastasis. By critically evaluating recent trends and comparing findings with current research, this review highlights the therapeutic value of these bioactive compounds. Additionally, the review discusses current knowledge gaps and proposes future research directions to optimize natural product-based interventions for PCa management.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147282870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design of Experiments-Based Formulation and Optimization of Oxaliplatin-Loaded Solid Lipid Nanoparticles for the Management of Colorectal Cancer.","authors":"Samanwita Khanra, Parikshit Roychowdhury, Nihar Ranjan Bhuyan, Gowthamarajan Kuppusamy, Kousalya Selvaraj, Jey Kumar Pachiyappan, Roshan P Rao, Imrankhan Nizam","doi":"10.2174/0115680096414252251125053406","DOIUrl":"https://doi.org/10.2174/0115680096414252251125053406","url":null,"abstract":"<p><strong>Introduction: </strong>Oxaliplatin is a third-generation platinum-based chemotherapeutic agent widely used for colorectal cancer treatment. However, its therapeutic application is limited by low solubility, systemic toxicity, and poor bioavailability.</p><p><strong>Methods: </strong>Solid lipid nanoparticles (SLNs) were prepared using a micro-emulsion technique and further optimized via Box-Behnken Design (BBD), considering key formulation variables including Glyceryl Monostearate, Soya Lecithin, and Tween 80. Nanoparticles were characterized by in vitro drug release, drug loading, encapsulation efficiency, zeta potential, particle size, and polydispersity index (PDI). Cytotoxic efficacy against the HT-29 colorectal cancer cell line was evaluated using the Sulforhodamine B (SRB) assay.</p><p><strong>Results: </strong>The optimized SLN formulation exhibited a mean particle size of 115.41 nm, PDI of 0.202, and zeta potential of +23.1 mV, indicating stability and efficient cellular uptake. Drug loading and encapsulation efficiency were 10.2 ± 0.4% and 92 ± 3.2%, respectively. In vitro release studies showed sustained drug release, reaching 97% over 48 hours. Cytotoxicity as-says demonstrated enhanced efficacy of Oxaliplatin SLNs, with IC₅₀ values of 0.9751 μg/mL at 24 h and 1.168 μg/mL at 48 h, compared to free Oxaliplatin (52.95 μg/mL at 24 h and 16.33 μg/mL at 48 h).</p><p><strong>Discussion: </strong>GMS-based SLNs optimized with Tween 80, lecithin, and DDAB exhibited ideal size, charge, and high encapsulation. FTIR and DSC analyses confirmed component compatibility. The formulation showed sustained release and enhanced cytotoxicity, highlighting its potential to improve Oxaliplatin delivery and therapeutic efficacy in colorectal cancer.</p><p><strong>Conclusion: </strong>The optimized Oxaliplatin SLNs demonstrated improved solubility, controlled release, and enhanced cytotoxicity, confirming their promise as a nanocarrier system for colorectal cancer therapy. Further in vivo studies are required to validate clinical effectiveness.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of pAHSG in Omental Metastasis of Ovarian Cancer: A New Perspective on Treatment.","authors":"Haiyan Chen, Shengyuan Jiang, Yixiao Wang, Yue Wu, Dake Li, Qiaoying Zhu, Kaipeng Xie","doi":"10.2174/0115680096402184251126105331","DOIUrl":"https://doi.org/10.2174/0115680096402184251126105331","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to characterize the polypeptide expression profiles in omental metastasis of Ovarian Cancer (OC) and explore their potential applications in the treatment of OC metastasis.</p><p><strong>Methods: </strong>Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) was employed to analyze the polypeptide profiles of primary OC tissues, omental metastatic tissues, and normal omental tissues from three OC patients. Differentially expressed polypeptides were screened using bioinformatics, and three polypeptides were synthesized to investigate their functional mechanisms in OC.</p><p><strong>Results: </strong>LC-MS/MS analysis revealed 127 differentially expressed polypeptides in omental metastatic tissues compared to primary OC tissues, and 171 differentially expressed polypeptides compared to normal omental tissues. Notably, a polypeptide derived from alpha-2-macroglobulin (pAHSG) was significantly downregulated in omental metastatic tissues compared to both normal omental tissues and primary OC tissues. In vitro experiments demonstrated that pAHSG inhibited the proliferation and invasion of OC cells in a concentration-dependent manner. Flow cytometry further indicated an increase in G1 phase cells and a reduction in S phase cells following pAHSG treatment. Pull-down assays combined with mass spectrometry identified 40 proteins interacting with pAHSG, and KEGG pathway analysis revealed their involvement in aminoacyl-tRNA biosynthesis and cancer-related pathways. Collectively, these findings suggest that the downregulation of pAHSG is closely associated with omental metastasis in OC.</p><p><strong>Discussion: </strong>The polypeptide expression profiles of omental metastatic tissues in OC exhibit significant alterations. The pAHSG effectively suppresses the malignant behaviors of OC cells, providing a novel potential target for the prevention and treatment of OC metastasis.</p><p><strong>Conclusion: </strong>Compared with primary OC tissues and normal omental tissues, the polypeptide expression profiles of omental metastatic tissues exhibit significant alterations. Notably, pA-HSG, whose level is significantly changed in metastatic tissues, can effectively inhibit the malignant behaviors of OC cells, thereby providing a novel potential target for the treatment of OC metastasis.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The FHL Protein Family in Cancer: Roles, Dysregulation, and Therapeutic Implications.","authors":"Yuanzhu Zhang, Zhenghui Tian, Qiming Fan, Kexin Zhang, Xiaodong Sun, Chengxia Kan, Fang Han","doi":"10.2174/0115680096412852251126052148","DOIUrl":"https://doi.org/10.2174/0115680096412852251126052148","url":null,"abstract":"<p><p>The four-and-a-half LIM (FHL) protein family, a subgroup of the LIM-only super-family, consists of cysteine-rich cytoskeletal proteins characterized by four-and-a-half LIM domains. These proteins display tissue-specific expression and diverse cellular functions, and accumulating evidence has linked their dysregulation to tumorigenesis. FHL proteins influ-ence key biological processes, including transcriptional regulation, cytoskeletal remodeling, cell proliferation, and signaling pathway modulation, thereby contributing to cancer initiation and progression. Depending on cellular and tissue context, they may function either as tumor suppressors or as oncogenic drivers. Recent studies have highlighted their diagnostic and prog-nostic potential, as aberrant expression of FHL proteins correlates with clinical outcomes in multiple malignancies. Moreover, growing attention has been directed toward their therapeutic relevance, with efforts focusing on targeting upstream regulatory mechanisms to modulate FHL activity. This review provides an integrated overview of the structural and functional features of the FHL protein family, summarizes current understanding of their roles in cancer biology, and discusses their potential as biomarkers and therapeutic targets. By outlining the mechanisms underlying their dysregulation, this work offers new perspectives on the biologi-cal significance of FHL proteins and their implications for cancer research and clinical prac-tice.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of CD24 Expression Enhances the Anti-Melanoma Effect of Endostatin by Ameliorating Anti-Tumor Immune Responses in Melanoma-Bearing Mice.","authors":"Mengyu Lei, Zhiang Liu, Fang Lu, Wufan Zu, Mingyao Li, Ming Wang, Chaohong Deng, Meihua Fan, Yuhao Cao, Sheng Guo, Huijie Jia, Ai Cui, Tiesuo Zhao","doi":"10.2174/0115680096419727251121103534","DOIUrl":"https://doi.org/10.2174/0115680096419727251121103534","url":null,"abstract":"<p><strong>Introduction: </strong>Melanoma is a highly aggressive skin cancer that arises from transformed epidermal melanocytes and is one of the malignancies with the fastest proliferation rates globally. Angiogenesis has been identified as a critical target for melanoma therapy, and endostatin has been verified to impede endogenous angiogenesis. However, some patients' therapeutic responses remain unsatisfactory. CD24, which functions as an anti-phagocytic signal, represents a potential target for tumor immunotherapy. Thus, in this study, we investigated the anti-melanoma effects of combined CD24 inhibition and endostatin treatment.</p><p><strong>Materials and methods: </strong>The co-expressed plasmid was constructed for functional verification. A melanoma-bearing mouse model was used to observe changes in tumor size during treatment. Protein expression, apoptosis, immune cell infiltration, and macrophage subset proportions were measured using Western blot, immunofluorescence, TUNEL, and flow cytometry assays.</p><p><strong>Results: </strong>The co-expressed plasmid significantly inhibited CD24 and VEGF expression in cells. The combination therapy promoted tumor cell apoptosis and decreased angiogenesis. It also increased infiltration of M1 macrophages, T lymphocytes, and NK cells in tumor tissue and the spleen. The combined plasmid-based therapy considerably suppressed tumor growth and lengthened the survival time of mice.</p><p><strong>Discussion: </strong>The combination therapy remodeled the immunosuppressive tumor microenvironment, enhancing M1 macrophage and T lymphocyte infiltration while suppressing angiogenesis via dual inhibition of CD24 and VEGF.</p><p><strong>Conclusion: </strong>Combining CD24 inhibition with antiangiogenic therapy could offer a novel therapeutic strategy for melanoma.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Thorny Question of Early Diagnosis in Lung Cancer: Should the IP-10 Cytokine be Brought to Trial?","authors":"Yvan Sinclair Ngaha Tchawe, Freddy Elad Essogmo, Ikenna Kingsley Uchendu, Abah Moses Owoicho, Angelina V Zhilenkova, Marina Prokhorova, Natalia Nikitina, Leonid N Bagmet, Alexander S Rusanov, Elena Evgeni'evna Shchelokova, Yuliya N Pirogova, Solomon Oloche Onoja, Precious Tochukwu Nwodo, Maurelle T Sikatie, Tatiana A Demura, Marina I Sekacheva","doi":"10.2174/0115680096415381251122002921","DOIUrl":"https://doi.org/10.2174/0115680096415381251122002921","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer remains the leading cause of cancer mortality worldwide, underscoring the need for non-invasive early diagnostic tools. IP-10, a cytokine involved in inflammation and angiogenesis, is a promising candidate. The present study aims to assess the relevance of IP-10 in lung cancer early diagnosis.</p><p><strong>Methods: </strong>In this cross-sectional study, we measured serum IP-10 levels using Luminex assays in 52 treatment-naïve lung cancer patients without comorbidities and 14 healthy controls. Based on the non-normal distribution of data, group comparisons were performed using Wilcoxon rank-sum tests. Multivariate linear regression was used to adjust for cofounders.</p><p><strong>Results: </strong>IP-10 levels were significantly elevated in lung cancer patients compared to healthy controls (median: 189.69 pg/mL vs. 108.78 pg/mL, p = 0.001). This significance persisted in the early-stage subgroup (stages 0-IIA; median: 192.49 pg/mL vs. 108.78 pg/mL, p = 0.001), even after multivariate adjustment (p = 0.018). Levels peaked in evolved early-stage disease (median: 241.42 pg/mL) before declining in advanced stages, while remaining elevated above controls.</p><p><strong>Discussion: </strong>The rise in IP-10 levels in early-stage lung cancer patients emphasizes its potential to serve as an early diagnostic biomarker. Meanwhile, the peak-and-decline pattern during phases of disease is consistent with its postulated dual role in early antitumor immunity and later tumor promotion.</p><p><strong>Conclusion: </strong>IP-10 can potentially be used as a supplemental serum biomarker for early lung cancer diagnosis. This finding calls for additional validation in bigger, multi-center cohorts to define diagnostic thresholds and investigate their incorporation into multi-marker panels.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulation of HSF-1 by FBXW7 to Alleviate Multidrug Resistance in Ovarian Cancer.","authors":"Fen Yang, Yiran Xiao, Xiaoni Zhou, Kaiyi Li, Gang Hu, Fujun Liu","doi":"10.2174/0115680096427366251126115802","DOIUrl":"https://doi.org/10.2174/0115680096427366251126115802","url":null,"abstract":"<p><strong>Introduction: </strong>Multidrug resistance (MDR) remains a major obstacle in the treatment of epithelial ovarian cancer (EOC). This study aimed to elucidate the regulatory role of FBXW7 in modulating the HSF-1/P-glycoprotein (P-gp) signalling axis and its impact on MDR in ovarian cancer.</p><p><strong>Materials and methods: </strong>Quantitative PCR, western blotting, immunohistochemistry, and immunofluorescence were employed to assess FBXW7, HSF-1, and P-gp expression in ovarian tissues and cell lines. Functional assays, including CCK-8 proliferation assays and lentiviral-mediated gene modulation, were conducted in SKOV3 and cisplatin-resistant SKOV3/DDP cells to evaluate the effects of FBXW7 on cell proliferation and drug resistance-associated pathways.</p><p><strong>Results: </strong>FBXW7 expression was markedly reduced in ovarian cancer tissues compared to normal controls and positively correlated with patient progression-free survival. Overexpression of FBXW7 suppressed proliferation in both SKOV3 and SKOV3/DDP cells and led to decreased HSF-1 and P-gp expression. Conversely, FBXW7 knockdown enhanced cell proliferation and upregulated the HSF-1/P-gp axis. Immunohistochemical and immunofluorescence analyses confirmed an inverse expression pattern between FBXW7 and HSF-1 in patient tissues.</p><p><strong>Discussion: </strong>The findings revealed FBXW7 to suppress multidrug resistance in ovarian cancer by downregulating the HSF-1/P-gp axis, thereby enhancing chemosensitivity. This study has highlighted a novel regulatory mechanism and suggested that restoring FBXW7 function may offer therapeutic benefit in overcoming chemoresistance.</p><p><strong>Conclusion: </strong>FBXW7 acts as a tumour suppressor that mitigates MDR in ovarian cancer by negatively regulating the HSF-1/P-gp pathway. The findings have offered mechanistic insights into chemoresistance and highlight the therapeutic potential of targeting FBXW7-HSF-1 signaling in EOC management.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological, Immunohistochemical, and Molecular Genetic Study on Pleomorphic Xanthoastrocytoma and Epithelioid Glioblastoma.","authors":"Peng Qi, I Weng Lao, Qianlan Yao, Xu Cai, Jian Wang, Xiaoyan Zhou","doi":"10.2174/0115680096378895251105050919","DOIUrl":"https://doi.org/10.2174/0115680096378895251105050919","url":null,"abstract":"<p><strong>Purpose: </strong>Currently, there is limited information available regarding the clinical features, pathological findings, and detailed molecular characteristics of pleomorphic xan-thoastrocytoma (PXA) and epithelioid glioblastoma (eGBM).</p><p><strong>Methods: </strong>In this study, we examined 11 PXA cases [9 grade 2 PXA (PXA G2) and 2 grade 3 PXA (PXA G3)] as well as 15 eGBM cases to investigate their histopathological and molecular associations.</p><p><strong>Results: </strong>Morphologically, PXA and eGBM exhibited distinct histological features. However, immunohistochemical analysis revealed no consistent differences between these glioma sub-types, with the exception of the Ki-67 labeling index. BRAF V600E mutation was detected in 60.0% of PXA cases and 85.7% of eGBM cases through immunohistochemistry (IHC) and/or sequencing, with complete concordance between the two methods. Molecular analysis further revealed that TERT promoter (TERT-p) mutation and copy number abnormalities were more prevalent in eGBM than in PXA.</p><p><strong>Conclusion: </strong>In conclusion, PXA and eGBM share similar clinical characteristics but exhibit different histological features. From a molecular perspective, PXA and eGBM belong to the same category and progress through the accumulation of genetic abnormalities, including TERT-p mutations, CDKN2A/B deletions, and TP53 mutations, based on the presence of BRAF mutation; however, larger sample sizes are required for validation.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Luteolin Isolated from Cuscuta Chinensis Lam Inhibits Lung Cancer Cell Viability and Migration via Co-Treatment with Mithramycin A.","authors":"Taierpuke Maimaiti, Mourboul Ablise, Aikebaier Maimaiti","doi":"10.2174/0115680096433191251202075137","DOIUrl":"https://doi.org/10.2174/0115680096433191251202075137","url":null,"abstract":"<p><strong>Introduction: </strong>As a common herbal medicine, Cuscuta chinensis Lam is widely used for cancer treatment in China. However, the anti-lung cancer effect of the bioactive constituents in C. chinensis and, the potential molecular mechanisms of action have yet to be elucidated.</p><p><strong>Materials and methods: </strong>Bioassay-guided fractionation was used to isolate luteolin from the water extract of C. chinensis (CLW). The structure of luteolin was determined by spectroscopic analysis. The viability of A549 and H1650 lung cancer cells was determined using the MTT assay. Annexin V-FITC staining assay and cell cycle analysis were performed to explore the apoptosis and cell cycle phase distribution of lung cancer cells, respectively. Transwell invasion, wound healing, transwell migration, and adhesion assays were conducted to observe the lung cancer cell invasion, migration, and adhesion. Protein expression was determined via Western blot analysis.</p><p><strong>Results and discussion: </strong>Luteolin was isolated from CLW by bioassay-guided fractionation, and its structure was determined by HR-ESI-MS and NMR. Luteolin inhibited the viability of A549 and H1650 lung cancer cells in a dose and time-dependent manner. Luteolin also dose-dependently induced apoptosis, and arrested the cell cycle at the G0/G1 phase in both cell types. Treatment with luteolin dose-dependently inhibited the invasion, migration, and adhesion of these cells. Luteolin consistently up-regulated FOSB, FGFBP1, and NPTX1 protein expression levels, and down-regulated H3K9me3, SETDB1, and MAP2K6 protein expression levels in A549 and H1650 cells. Co-treatment of luteolin and mithramycin A on A549 and H1650 lung cancer cells exhibited stronger up-regulation of FOSB and NPTX1 protein expression levels, and stronger down-regulation of SETDB1, H3K9me3, and MAP2K6 protein expression levels than luteolin or mithramycin A treatment alone. Co-treatment of luteolin and mithramycin A synergistically inhibited A549 and H1650 cell viability; induced apoptosis; delayed cell cycle at the G0/G1 phase; and inhibited the invasion, migration, and adhesion of A549 and H1650 cells compared with the treatment of luteolin or mithramycin A alone.</p><p><strong>Conclusion: </strong>Luteolin may suppresses the viability, invasion, migration, and adhesion of lung cancer cells via co-treatment with mithramycin A.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}